| Autor: |
Kokkotou E; Oncology Unit, Third Department of Medicine, 'Sotiria' General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece., Anagnostakis M; Oncology Unit, Third Department of Medicine, 'Sotiria' General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece., Evangelou G; Oncology Unit, Third Department of Medicine, 'Sotiria' General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece., Syrigos NK; Oncology Unit, Third Department of Medicine, 'Sotiria' General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece., Gkiozos I; Oncology Unit, Third Department of Medicine, 'Sotiria' General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece. |
| Abstrakt: |
Conventional cancer clinical trials can be time-consuming and expensive, often yielding results with limited applicability to real-world scenarios and presenting challenges for patient participation. Real-world data (RWD) studies offer a promising solution to address evidence gaps and provide essential information about the effects of cancer treatments in real-world settings. The distinction between RWD and data derived from randomized clinical trials lies in the method of data collection, as RWD by definition are obtained at the point of care. Experimental designs resembling those used in traditional clinical trials can be utilized to generate RWD, thus offering multiple benefits including increased efficiency and a more equitable balance between internal and external validity. Real-world data can be utilized in the field of pharmacovigilance to facilitate the understanding of disease progression and to formulate external control groups. By utilizing prospectively collected RWD, it is feasible to conduct pragmatic clinical trials (PCTs) that can provide evidence to support randomized study designs and extend clinical research to the patient's point of care. To ensure the quality of real-world studies, it is crucial to implement auditable data abstraction methods and develop new incentives to capture clinically relevant data electronically at the point of care. The treatment landscape is constantly evolving, with the integration of front-line immune checkpoint inhibitors (ICIs), either alone or in combination with chemotherapy, affecting subsequent treatment lines. Real-world effectiveness and safety in underrepresented populations, such as the elderly and patients with poor performance status (PS), hepatitis, or human immunodeficiency virus, are still largely unexplored. Similarly, the cost-effectiveness and sustainability of these innovative agents are important considerations in the real world. |
